DGAP-Ad-hoc: HAEMATO AG / Key word(s): Dividend
HAEMATO AG: Dividend of EUR 1.10
Berlin, May 3, 2022 - At today's balance sheet meeting, the annual financial statements 2021 of HAEMATO AG, which were issued with an unqualified audit certificate, were adopted. The preliminary figures were confirmed. The Executive Board and Supervisory Board will propose a dividend of EUR 1.10 per dividend-bearing share to the Annual General Meeting to be held in presence on July 12, 2022.
HAEMATO AG was founded in 1993 and is a pharmaceutical company focusing on the trade of high-priced specialty pharmaceutical drugs (with the therapeutic focus on oncology, HIV, rheumatology and other chronic diseases) as well as the development and distribution of medical products and private brands, especially in the area of "Lifestyle & Aesthetics". HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. For further information, please visit www.haemato.de.
HAEMATO AG, Investor Relations
Telefon: +49 (0)30 897 30 86 70
03-May-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Phone:||+49 (0)30 897 30 86 70|
|Fax:||+49 (0)30 897 30 86 79|
|Listed:||Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange|
|EQS News ID:||1342367|
|End of Announcement||DGAP News Service|
1342367 03-May-2022 CET/CEST